Literature DB >> 21091099

Economic benefit of a 1-day reduction in hospital stay for community-acquired pneumonia (CAP).

C M Kozma1, M Dickson, M K Raut, S Mody, A C Fisher, J R Schein, J I Mackowiak.   

Abstract

OBJECTIVE: As a component of healthcare reform, payers, hospital administrators, and physicians are looking for ways to reduce hospital expenditures and improve efficiency. The economic benefit of a reduced hospital stay must be weighed against the cost of the treatment or process necessary to achieve the reduced length of stay (LOS). The objective of this paper was to estimate the potential economic benefit of a reduction in inpatient hospital LOS for a common type of admission, community acquired pneumonia (CAP). RESEARCH DESIGN AND METHODS: Data for this study were from the CAP hospital admissions selected from the 2006 Healthcare Cost and Utilization Project (HCUP) National Inpatient Sample (NIS). Potential savings associated with a 1 day reduction in CAP LOS were estimated using three methods: (1) average cost, (2) weighted-average incremental cost of an additional day, and (3) weighted-average predicted mean costs from regression models which were used to estimate incremental cost adjusting for hospitalization characteristics. MAIN OUTCOME MEASURES: Cost per day of CAP hospitalization.
RESULTS: A total of 1,471,295 CAP admissions qualified for the analysis. The cost for each day of reduction in LOS in 2009 US dollars was $2273, $2373, and $2319 for the three methods: simple average, incremental, and regression, respectively. Subgroup analysis and regression analysis indicated higher costs were identified: in patients who died in the hospital, had hospital stays in the Northeast or West, and in large hospitals. Longer CAP hospitalizations had a higher cost per additional day. Limitations include those typically associated with the use of administrative claims (e.g., lack of clinical detail, issues related to diagnosis coding).
CONCLUSIONS: Eliminating a day during the course of a CAP admission is potentially worth $2273-2373 in economic benefits (2009 dollars). As we strive for greater efficiency in healthcare delivery, changes in processes and/or improved diagnostics or treatments may potentially achieve a reduction in the length of stay. The cost of such changes or improvements must be weighed against the economic benefit of a shorter hospitalization.

Entities:  

Mesh:

Year:  2010        PMID: 21091099     DOI: 10.3111/13696998.2010.536350

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  11 in total

1.  A tailored implementation strategy to reduce the duration of intravenous antibiotic treatment in community-acquired pneumonia: a controlled before-and-after study.

Authors:  M F Engel; A H W Bruns; M E J L Hulscher; C A J M Gaillard; S U C Sankatsing; F Teding van Berkhout; M H Emmelot-Vonk; E M Kuck; M H M Steeghs; J H den Breeijen; R K Stellato; A I M Hoepelman; J J Oosterheert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-26       Impact factor: 3.267

2.  Increased resource use in lung transplant admissions in the lung allocation score era.

Authors:  Bryan G Maxwell; Joshua J Mooney; Peter H U Lee; Joseph E Levitt; Laveena Chhatwani; Mark R Nicolls; Martin R Zamora; Vincent Valentine; David Weill; Gundeep S Dhillon
Journal:  Am J Respir Crit Care Med       Date:  2015-02-01       Impact factor: 21.405

3.  Effect of Early Mobility as a Physiotherapy Treatment for Pneumonia: A Systematic Review and Meta-Analysis.

Authors:  Tania Larsen; Annemarie Lee; Dina Brooks; Stephanie Michieli; Meaghan Robson; Jenna Veens; Olivia Vokes; S Deborah Lucy
Journal:  Physiother Can       Date:  2019       Impact factor: 1.037

4.  Determining the duration of therapy for patients with community-acquired pneumonia.

Authors:  Nikole M Scalera; Thomas M File
Journal:  Curr Infect Dis Rep       Date:  2013-04       Impact factor: 3.725

5.  Discordance of physician clinical judgment vs. pneumonia severity index (PSI) score to admit patients with low risk community-acquired pneumonia: a prospective multicenter study.

Authors:  Pedro J Marcos; Marcos I Restrepo; Francisco J González-Barcala; Nilam J Soni; Iria Vidal; Pilar Sanjuàn; Diego Llinares; Lucía Ferreira-Gonzalez; Carlos Rábade; Isabel Otero-González; Pedro Marcos; Héctor Verea-Hernando
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

6.  Association Between Initial Route of Fluoroquinolone Administration and Outcomes in Patients Hospitalized for Community-acquired Pneumonia.

Authors:  Raquel K Belforti; Tara Lagu; Sarah Haessler; Peter K Lindenauer; Penelope S Pekow; Aruna Priya; Marya D Zilberberg; Daniel Skiest; Thomas L Higgins; Mihaela S Stefan; Michael B Rothberg
Journal:  Clin Infect Dis       Date:  2016-04-05       Impact factor: 9.079

7.  Cost-Saving Opportunities with an Oral and Intravenous Once-Daily Aminomethylcycline Antibiotic for Hospitalized Patients with Community-Acquired Bacterial Pneumonia: Findings from Decision-Analytic Models.

Authors:  Thomas Lodise; Kenneth LaPensee
Journal:  Am Health Drug Benefits       Date:  2019 Jun-Jul

8.  Budget Impact of Omadacycline for the Treatment of Patients with Community-Acquired Bacterial Pneumonia in the United States from the Hospital Perspective.

Authors:  Kenneth LaPensee; Rohit Mistry; Thomas Lodise
Journal:  Am Health Drug Benefits       Date:  2019-02

Review 9.  Community-acquired pneumonia: an unfinished battle.

Authors:  Girish B Nair; Michael S Niederman
Journal:  Med Clin North Am       Date:  2011-10-05       Impact factor: 5.456

10.  Burden of community-acquired pneumonia in adults over 18 y of age.

Authors:  Filiz Kosar; Devrim Emel Alici; Basak Hacibedel; Burcu Arpınar Yigitbas; Pejman Golabi; Caglar Cuhadaroglu
Journal:  Hum Vaccin Immunother       Date:  2017-03-10       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.